CLOV: Revenue and profitability strengthened as FY26 guidance rose across all listed metrics

Less than 1 min read

3Q26 revenue grew 53% YoY, with GAAP net income of $6M and Adjusted EBITDA of $16M. FY26 guidance improved across all listed metrics, alongside strong MA membership growth and a leading PPO quality rating.

Original document: [Clover Health Investments, Corp. [CLOV] Slides Release — Nov. 4 2026](https://www.tradingview.com/accounts/signin?next=https%3A%2F%2Fnews-mediator.tradingview.com%2Fdoc-screener%2Fv1%2Ffiles%2Furn%3Aslides%3Aquartr.com%3A4249060-7ffe63b2931512a724680f1a4424f4f3)

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.